Upstream Processing

Large-scale single-use bioreactors prove successful as limits are tested.

SUB bioreactor performance has had seen its limits and successes.

Advancements in bioprocessing technologies test microbial fermentation adaptability.

The benefits of single-use technologies for upstream viral-vector processes clearly outweigh their disadvantages.

Catalent Biologics has launched its new cell line expression technology, GPEx Lightning, which aims to shorten drug substance development timelines by up to three months.

The collaboration continues as the companies design bioprocess impurity reagent sets to detect residual HCP from HEK 293 cells.

The acquisition of Intermountain Life Sciences will double Cytiva’s capacity for buffers and liquid cell culture media at its manufacturing site in Logan, Utah.

Cell-free expression is promising in preclinical applications, but still presents challenges to scale up for commercial production.

VectorY, a Netherlands-based biotechnology company, has been selected as the European winner of MilliporeSigma’s 2021 Advance Biotech Grant Program.

Demand for recombinant microorganism-based cell culture supplements is rising on the back of lower contamination risk.

Biopharmaceutical companies and contract manufacturers respond to changing demand dynamics for upstream bioprocessing capacity.

The innovation of single-use technologies is applicable early on in the manufacturing process.

Overcoming time and cost constraints can help enable seed train intensification efforts to maximize product yield.

Connected, integrated bioprocessing enterprises with greater data analytics capabilities are coming.

Cell-culture optimization may see benefits from a synthetic biology-based approach that improves product titer, quality, and time.

Establishing an automated inline dilution system can potentially ease bottlenecking delays resulting from higher upstream yields.

PAT advances are enabling improved process understanding, process control, and error prevention.

An innovation such as synthetic biology can develop a consistently stable starting cell line for cell therapy source material.

Bioreactor technology advances can offer seamless manufacturing scale-up and can reduce the timeline and cost of biologics production.

This article will explore the traditional path from the laboratory to the clinic and how the fixed-bed technology provides an alternative solution to meet commercial demands.

Process modeling offers an opportunity to troubleshoot for and anticipate difficult aspects of a bioprocess.

Innovative approaches, including ready-to-use materials and in-line dilution, can significantly streamline overall bioprocessing operations.

Therapies for early and late treatment and passive immunization of COVID-19 are needed and can be developed using antibodies from recovered patients.

Synthetic biology has advanced the scope and scale with which biologically derived therapeutics can be developed.

New bioreactor designs, coupled with better media, process intensification and analytics, continue to improve upstream bioprocessing.

The new BIOSTAT STR Generation 3 with BIOBRAIN bioproduction platform offers process intensification with automated feed and bleed and integrated cell retention functionality.

Better understanding and control of cell behavior is yielding benefits, upstream and beyond.

The future of raw material sourcing for mAb production may lay in the sustainability of the source and the added benefits of newer technologies.

By establishing effective management of data and knowledge, it will be possible to employ advances, such as artificial intelligence and synthetic biology, to their full potential in upstream bioprocessing.

The production of viral vectors for use in gene therapy benefits from being able to use similar cell-culture processes as mAbs, but it faces limitations under current cell-culture technologies.